Novartis and AveXis shares saw big gains in Monday trading after it was announced that the Swiss drugmaker would be buying the gene therapy company for $8.7 billion in cash. Novartis announced that it would be paying $218 a share for AveXis, a number that represents a 72% premium compared to the stock’s 30-day volume … Continue reading “Novartis Just Made an $8.7 Billion Dollar Bet on this Gene Therapy Company”
